Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)



Status:Archived
Conditions:Cancer, Blood Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:September 2009

Use our guide to learn which trials are right for you!

A Dose Escalation Study to Determine the Absolute Bioavailability of a Single Oral Dose Administration of Decitabine in Patients With Myelodysplastic Syndrome (MDS)


The purpose of this study is to determine how the body absorbs decitabine when taken orally
in patients with Myelodysplastic Syndrome (MDS). Safety will also be assessed for this oral
dose.


Cohorts are dosed sequentially, and escalation may stop before the 5th cohort is dosed.
Each cycle will be approximately 4 weeks in length. Following Cycle 1, patients may receive
an additional 4 follow-up cycles of decitabine. Cycles 2-5 will include a 20 mg/m^2 1-hour
IV infusion of decitabine on Days 1-5 for all cohorts.


We found this trial at
6
sites
Albany, New York
?
mi
from
Albany, NY
Click here to add this to my saved trials
Austin, Texas
?
mi
from
Austin, TX
Click here to add this to my saved trials
1351 Kimberly Rd
Bettendorf, Iowa 52722
(563) 355-7733
Hematology Oncology Associates of the Quad Cities
?
mi
from
Bettendorf, IA
Click here to add this to my saved trials
Denver, Colorado
?
mi
from
Denver, CO
Click here to add this to my saved trials
Mountlake Terrace, Washington
?
mi
from
Mountlake Terrace, WA
Click here to add this to my saved trials
Peoria, Arizona
?
mi
from
Peoria, AZ
Click here to add this to my saved trials